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5-FU therapeutic monitoring with dose adjustment leads to an
improved therapeutic index in head and neck cancer
J. Santini, G. Milano, A. Thyss, N. Renee, P. Viens, P. Ayela, M. Schneider &
F. Demard
Centre Antoine Lacassagne, 36 Voie Romaine, 06054 Nice Cedex, France.
Summary This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin
plus continuous 5-day 5-FU as first-line chemotherapy of head and neck cancer, and the benefit of such data
for real-time therapy management. Pharmacokinetic analysis of 177 cycles for 77 patients from a group of 89
patients (group 1; 228 cycles) revealed that both the time-concentration product (AUC) for the entire cycle
and the half-cycle AUC (AUCO3days) were predictive of cycle toxicity. Real-time analysis of individual
AUCO-3 days was used to decide whether to reduce the dose during the second half of the cycle for a total of
249 cycles (81 patients; group 2). The dose in the second half of the course was reduced in 40% of the group 2
courses. There was a statistical difference in complete response rates between group 1 (31%) and group 2
(47%), (0.02<P<0.05) and a statistically significant reduction was observed in the incidence of toxic cycles
(>grade 2, group 1=20% versus group 2 = 12.4%; 0.02<P<0.05). Pharmacokinetic follow-up of these
patients has proved to be an objective means to improve therapeutic index significantly.
In addition to the digestive tract, where its efficacy remains
limited (Buroker et al., 1985), chemotherapy by 5-FU is used
for other disease sites. In squamous cell carcinoma of the
head and neck very high response rates have been observed
when the drug is combined with cisplatin (CDDP)
(Thyss et al., 1986b; Amrein & Weitzman, 1985; Kish et al.,
1982). This combination protocol is accompanied by a
significant incidence of toxicity (Amrein & Weitzman, 1985)
that is often acceptable but sometimes severe, depending on
the dose (Merlano et al., 1987) or the specific site (Kies et
al., 1987).
One of the major objectives of clinical pharmacokinetics is
to improve the therapeutic index on an individual patient
basis. For a limited population of head and neck carcinoma
patients treated by CDDP-5-FU, we previously showed that
the digestive tract and/or haematological tolerance was
linked to the degree of total body exposure to the drug
during the cycle (C xT, area under curve, AUC) (Thyss et
al., 1986a).
The first part of the present study extends and confirms
this result on a larger population. In the second stage, data
obtained were used for a prospective study in an attempt to
improve the therapeutic index.
Subjects and methods
Study population
A total of 170 patients with squamous cell carcinoma of the
head and neck treated at our institution between 1983 and
1987 were investigated. There were 145 men and 25 women,
mean age 61 years (range 36-82). A total of 477 chemo-
therapy cycles were analysed.
Group 1 (89 patients, 228 cycles) corresponds to a retro-
spective study during which 5-FU blood concentrations were
measured systematically for each individual cycle of 77
patients (177 cycles). This group of patients allowed
comparison of the distribution of AUC values as a function
of response and tolerance to treatment. Group 2 (81
patients, 249 cycles) corresponds to patients entered into a
prospective study based on the conclusions of the initial data
obtained for group 1.
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Chemotherapy regimen
Treatment was as follows. Day 0, 6h hydration with 5%
dextrose (2 litres), NaCl (6gl-1), and KCI (3gl-1), followed
by CDDP (100mgm-2) 1 mgmin-1 i.v. in normal saline
(0.5litres) with 1.6% mannitol (0.25litres), and then 5%
dextrose (1 litre), NaCl (6gI-1) and KCI (3g -1). Days 1-5,
5-FU 1,000mgm-2 24h 1 by continuous i.v. infusion with a
controlled flow pump. The scheduled protocol called for
three courses per patient every three weeks.
Evaluation of response and toxicity
Response was evaluated by the same physician 10 days after
completion of the last chemotherapy course. Clinical
response was defined using the product of two perpendicular
lesion diameters. Complete response (CR) corresponded to
disappearance of all clinically visible or palpable lesions;
partial response (PR) was defined as tumour regression of
over 50%; no response (NR) corresponded to tumour
regression of 50% or less, stable disease or progressive
disease. For the patients who underwent surgery after
chemotherapy, the histological response was evaluated by
examining the surgical specimen. Haematological and
digestive tract toxicities were evaluated using WHO criteria.
Only haematological and digestive tract toxicities, including
stomatitis, were considered because they are the most
frequent for this protocol and necessitate dose reduction and
treatment interruption. Other toxicities are rare, e.g. cardiac
toxicity (Thyss et al., 1987) and neurological toxicity (Weiss
et al., 1974), or without therapeutic consequences (alopoecia,
cutaneous toxicity).
Pharmacokinetic analysis
Two blood samples were collected every day (8 a.m., 5 p.m.)
during each 5-FU course. Venous blood (5ml) was drawn on
EDTA tubes and samples were immediately brought to the
laboratory and centrifuged (Omin, 2,500r.p.m.). Plasma was
stored at -200C until analysed (within 1-3 days). For group
2, the tubes corresponding to the first two days of 5-FU
administration and the tube obtained at 8a.m. on the third
day (first half of the 5-FU cycle) were all analysed on the
morning of the third day to determine the half-cycle AUC
(AUCO-3 days) and thus modify or not the second half-cycle
5-FU dose. A previously described HPLC technique
(Christophidis et al., 1979) was used for 5-FU measurements.
The limit of sensitivity was 5 ngml- . AUC (product of
concentration per time, area under curve) was calculated by
Br. J. Cancer (1989), 59, 287-290 ,'-. The Macmillan Press Ltd., 1989288 J. SANTINI et al.
the trapezoidal rule using an appropriate programme.
AUCO.3days was calculated from 0 to 48h of the 5-FU cycle
(8 a.m. on the third day of the cycle) and AUCO5days
was determined from 0 to 105h (5p.m. on the fifth day of
the cycle).
Statistics
Comparisons of distribution of AUC values were made using
Student's t test. Threshold values were tested using the x2
test. The comparison for tumour stage repartition, response
and toxicity between groups 1 and 2 was made using the x2
test.
Results
Figure 1 shows the respective distribution of individual 5-FU
AUC values for all group 1 courses with respect to toxic and
non-toxic courses. Comparisons were made for total course
AUC (AUCO, 5 days) and first half-course AUC (AUCO3 days)
Although there was some overlap in the data, the
distributions were significantly different between toxic and
non-toxic courses. Median values were respectively
(ngml-1h-) for non-toxic cycles: 5,500 (AUCO3 days) and
26,000 (AUCO5 days) and for toxic cycles: 11,000 (AUCO3 days)
and 34,000 (AUCOsdays). We identified a threshold
AUCO-3days value of 15,000ngml-Ph-1 that predicted cycle
toxicity (X2=39.8, P<0.001).
Table I shows the mean AUC values for the first half of
the cycle for group 1 patients as a function of tumoral
response. Mean values were lowest for non-responders (NR)
and highest for complete responders (CR), but differences
were not statistically significant because of the great degree
of variability. It was decided to use AUCO3 days data to
establish a diagram (Figure 2) for treatment monitoring in a
prospective study group, group 2 (see Appendix 1). For all
patients and all cycles of group 2 the AUCD3 days value was
used to determine the extent of reduction (if required) of the
5-FU dose for the second half of the cycle.
Table II shows the respective initial tumour stages,
treatment responses and toxicity rates in groups 1 and 2. The
initial tumour stage profile was not significantly different
between groups 1 and 2. Moderate and severe toxicity
(>grade 2) were reduced from 20% (group 1) to 12.4%
(group 2), 0.02<P<0.05. Severe toxicity was reduced from
9% (group 1) to 6% (group 2), n.s. The dose in the second
half of the course was reduced in 40% of cycles; most 5-FU
reductions were between 30 and 50% of the scheduled dose
for days 3-5. Responses were significantly higher in group 2
(47% CR) compared with group 1 (31% CR), 0.02<P <0.05.
Also, 15% more cycles could be administered to group 2
than to group 1.
Discussion
Multiple-drug chemotherapy using CDDP and 5-FU is one
of the most efficient first-line therapeutic approaches for
advanced head and neck carcinomas. While treatment
tolerance is usually acceptable, a non-negligible incidence of
toxicity has been reported (Merlano et al., 1987; Amrein &
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Figure 1 5-FU AUC distribution in group 1 for toxic (T) and
non-toxic courses (NT). Horizontal lines indicate median values.
Table I 5-AUCO3days (ngml-1 h-) and response in group 1
No. of patients Mean Standard deviation
NR 12 8,800 5,061
PR 33 9,735 5,817
CR 20 13,200 14,900
For definition of response see Subjects and methods. Sixty-
two patients in group 1 were available for response NR
versus CR, Student's t test=0.99, n.s.
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Figure 2 Diagram for 5-FU doses delivery during the second
half of the cycles as a function of 5-FU AUCO3days- See
Appendix 1 for detailed explanations.
Table II Toxicity and response in groups 1 and 2
Initial stage
ofprimary tumour % Toxic cycles % Response to therapy
TJ T2 % T3 T4% Gde 2 Gde 3,4 Gde 2,3,4 NR PR CR PR+CR
Group 1 32 68 12 9 20 19 50 31 81
Group 2 48 52 6.4 6 12.4 14 39 47 86
Comparison n.s. n.s. P<0.01 n.s. 0.02<P<0.05 n.s. n.s. 0.02<P<0.05 n.s.
For definition of toxicity and response see Subjects and methods.
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Weitzman, 1985). In this combination regimen, continuous
5-FU administration (Amrein & Weitzman, 1985) has
improved haematological tolerance in comparison with bolus
injections (Merlano et al., 1987). Stomatitis remains the
major toxicity with continuous 5-FU; the frequency was 21%
in 131 treatment cycles reported by Amrein & Weitzman
(1985).
Toxicity may lead to lengthening of the interval between
cycles and to reduction in the total number of cycles
scheduled. In both cases, the dose intensity is reduced. This
might be expected to compromise the cytotoxic activity of a
phase-specific drug such as 5-FU. Indeed, clinical experience
has shown that the number of CDDP-5-FU cycles is of
prime importance for the complete response rate and
survival in advanced head and neck cancer (Rooney et al.,
1984). In these patients (Thyss et al., 1986b), we previously
found that the clinical response to CDDP-5-FU is a major
prognostic factor. It is thus important not to shorten the
chemotherapy programme because of excessive, un-
anticipated toxicity.
One of the ultimate goals in clinical pharmacokinetics of
anticancer agents is effective improvement of the therapeutic
index of treatments (Sulkes & Collins, 1987; Allen, 1983).
This 4-year study conducted on 170 patients receiving a total
of 477 CDDP-5-FU cycles attains this goal and confirms our
previous results (Thyss et al., 1986a). This study involved
two sequential stages: a retrospective pharmacokinetic
analysis followed by a prospective evaluation. Tolerance to
treatment was significantly improved. Haematological and/or
digestive tract toxicity attributable to 5-FU was reduced
from 20 to 12.4%. Moreover, although dose reduction was
performed in 40% of cycles in group 2, the complete
response rate was significantly higher than in group 1 (Table
II). The proportion of advanced stages (T3, T4) was not
significantly different, and thus cannot explain the difference
in response rates between the two groups. In fact, due to a
better tolerance in group 2, treatment compliance was
greater than in group 1. It is likely that the difference in
response rates may be due to a difference in treatment
intensity between the two groups. It must be kept in mind
that at the target level 5-FU by itself is not active and must
be transformed into FUTP and FdUMP to be cytotoxic
(Myers, 1981). These key biochemical steps are thus decisive
in the activity of the drug.
The possibility of giving more drug to a patient with a low
AUC during the first half of the cycle could be justified
pharmacologically. If mean values are considered, the AUC
values of the first half of cycle were lower for non-
responders than for complete responders (Table I). However,
the high interpatient variability in this pharmacokinetic
parameter prevented the drawing of statistically significant
conclusions. This particular point merits re-evaluation on a
larger group of patients. However, for patients with a very
low AUCO3 days (<5,000ngml- h-), it might be advisable
to increase the 5-FU dose for the second half of the cycle in
order to obtain an increased chance of better response.
These results emphasise the role of drug AUC as one of
the best pharmacokinetic parameters for predicting pharma-
codynamic events (Powis, 1985). HPLC is now widely used
in most clinical biochemistry laboratories and 5-FU analysis
can thus be easily performed on a routine basis to monitor
treatment. The cost of our policy is evaluated in Appendix 2.
We believe that pharmacokinetic follow-up of these patients
is an objective means to improve their therapeutic index
significantly.
Appendices
Appendix 1: Construction and use of Figure 2
The line has been determined as follows: 15,000 ngml1h1
is the cut-off value separating significantly toxic from non-
toxic cycles in group 1. This was the starting point for
reducing or not the 5-FU dose for the second part of the
cycle in group 2. We estimated that a 30% dose reduction
(corresponding to 70% of the initial dose scheduled) would
lead to an objective decrease in steady state blood 5-FU. On
the other hand, above an AUCO3 days of 30,000 ngml- h-I
all cycles were toxic in group 1. This value is also close to
the median of AUCO5 days for non-toxic cycles of group 1.
Thus above this AUCO3 days threshold it was decided to stop
giving 5-FU during the second part of the cycle in group 2.
For a given patient, X, receiving 1.7g 5-FU per day if
AUCO3 days=20,000ngml 1 h-1 at the third day of the cycle
then the 5 FU dose will be changed to 0.77g per day for the
second part of the cycle (45% of the initial dose), in
accordance with the figure found on the y-axis after the
intercept with the line of the 20,000 value from the x-axis.
For another patient, Y, receiving 1.8g per day and with an
AUCO3 days of 10,000 ng ml-1h-1, the 5-FU dose delivered
during the second part of the cycle will be the same 1.8g per
day because 10,000ngml1 h1 is below the x-axis threshold
of 15,000ngml-1h-1.
Appendix 2: Cost of 5-FU monitoring
Because HPLC is now widely used with a high versatility in
most clinical biochemistry laboratories, its specific cost for
the 5-FU analysis can be ignored. Nine blood samples are
measured per 5-FU cycle (5p.m. day 1, 8a.m. and 5p.m.
days 2, 3, 4 and 5) resulting in 27 5-FU analyses per complete
treatment course of three cycles. With our analytical
conditions 200 samples can be measured with an HPLC
column (mean cost of 2,000FF) thus leading to a cost of
270FF per chemotherapy course per patient. Cost for water
and salts of the HPLC buffer is negligible. We evaluated
that, in our institute, 5-FU analysis for one cycle of 5-FU
takes two man hours.
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